Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: CYPH cypherpunk.com
Cypherpunk Technologies Inc. is a privacy technology company that pursues its mission through two primary strategies: accumulating Zcash (ZEC), a privacy-focused digital currency utilizing zero-knowledge proofs, and investing in, acquiring, and building technologies that advance internet privacy. The company holds approximately 323,394 ZEC, representing roughly 1.92% of the total circulating supply of the Zcash network, making it a significant institutional holder of the digital asset. Through its subsidiary Leap Therapeutics, Cypherpunk is also developing novel cancer therapies, including sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody with FDA Fast Track designation targeting DKK1-high metastatic colorectal cancer, and FL-501. The company trades on the Nasdaq Capital Market under the ticker CYPH. Updated
Tyler and Cameron Winklevoss’s investment fund has announced plans to potentially invest up to $100 million in a new Winklevoss Zcash ETF. This fund would hold Zcash (CRYPTO:ZEC) and trade on Nasdaq…
Cypherpunk Technologies Inc. is a privacy technology company that pursues its mission through two primary strategies: accumulating Zcash (ZEC), a privacy-focused digital currency utilizing zero-knowledge proofs, and investing in, acquiring, and building technologies that advance internet privacy.
The Wall Street consensus 12-month price target for CYPH is $4.90.
